Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | CHOSA ONCOLOGY AB: Chosa Oncology announces outcome in rights issue | 2 | Cision News | ||
Mi | CHOSA ONCOLOGY AB: Last subscription day in Chosa's subscription period | 2 | Cision News | ||
Mi | CHOSA ONCOLOGY AB: CHOSA files new patent application to predict which patients may benefit from platinum chemotherapy and immunotherapy | 5 | Cision News | ||
13.06. | Bulletin from the annual general meeting on 13 June 2025 in Chosa Oncology AB | 1 | Cision News | ||
12.06. | The subscription period in Chosa Oncology AB's rights issue begins today - the company invites to a webcast presentation | 2 | Cision News | ||
CHOSA ONCOLOGY Aktie jetzt für 0€ handeln | |||||
10.06. | Chosa Oncology AB publishes information document in connection with rights issue of units | 2 | Cision News | ||
09.06. | CHOSA ONCOLOGY AB: CHOSA Oncology invites investors to two upcoming presentations | 1 | Cision News | ||
06.06. | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.06.2025 | 264 | Xetra Newsboard | Das Instrument 37P FR0010341032 FONCIERE INEA SA EO 14,39 EQUITY wird cum Kapitalmassnahme gehandelt am 06.06.2025 und ex Kapitalmassnahme am 09.06.2025 The instrument 37P FR0010341032 FONCIERE INEA... ► Artikel lesen | |
03.06. | Spotlight Stock Market: Market Notice 101/25 - Information regarding the rights issue from CHOSA Oncology AB | 3 | Cision News | ||
02.06. | Chosa Oncology AB resolves on a directed issue of units and on a rights issue of units to provide funds for reaching several value-enhancing milestones | 3 | Cision News | ||
23.05. | CHOSA ONCOLOGY AB: CHOSA submits ESMO abstract on carboplatin response in breast cancer patients | 2 | Cision News | ||
13.05. | Notice of annual general meeting in Chosa Oncology AB | 2 | Cision News | ||
09.05. | CHOSA ONCOLOGY AB: CHOSA- Extending CHOSA's Platin DRP: Predicting Carboplatin Efficacy in Breast Cancer | 2 | Cision News | ||
26.03. | CHOSA ONCOLOGY AB: CHOSA to Unveil Predictive Data for Cisplatin Response in Lung Cancer at end Q2 2025 - Advancing Precision Medicine for the World's Most Widely Used Cancer Drug | 3 | Cision News | ||
10.02. | CHOSA ONCOLOGY AB: CHOSA announces a new collaboration with lung cancer experts paving the way for integration into clinical guidelines | 1 | Cision News |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
CLIMB BIO | 1,180 | -6,35 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen | |
BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |